Provided by Tiger Trade Technology Pte. Ltd.

Insight Molecular Diagnostics Inc.

3.59
+0.21006.21%
Post-market: 3.57-0.0200-0.56%19:53 EDT
Volume:287.13K
Turnover:1.01M
Market Cap:117.48M
PE:-2.45
High:3.67
Open:3.40
Low:3.31
Close:3.38
52wk High:8.51
52wk Low:2.42
Shares:32.72M
Float Shares:10.41M
Volume Ratio:0.69
T/O Rate:2.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4638
EPS(LYR):-1.6500
ROE:-23603.11%
ROA:-57.82%
PB:-5.52
PE(LYR):-2.18

Loading ...

Insight Molecular Diagnostics says Clinical Chemistry study shows 99.2% agreement between GraftAssure and rival NGS dd-cfDNA test at 0.5% threshold

Reuters
·
Jun 17

Insight Molecular Diagnostics says study shows GraftAssure CM-Score lifts kidney transplant rejection PPV to 81%

Reuters
·
Jun 12

Insight Molecular Diagnostics to showcase GraftAssure at American Transplant Congress

Reuters
·
Jun 10

iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

GlobeNewswire
·
Jun 10

We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate

Simply Wall St.
·
May 15

Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)

TIPRANKS
·
May 14

Insight Molecular Diagnostics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Insight Molecular Diagnostics Q1 FY26 net loss narrows to $4.29 million; revenue drops to $32,000

Reuters
·
May 14

Insight Molecular Diagnostics amends 8-K, reclassifies Quest agreement disclosure to Item 8.01

Reuters
·
May 14

Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate

Benzinga Earnings
·
May 14

Imdx Reports Q1 2026 Results and Update on Progress Toward Graftassure Commercialization

THOMSON REUTERS
·
May 14

Insight Molecular Diagnostics Inc Q1 Pretax Profit USD -4.29 Million

THOMSON REUTERS
·
May 14

Press Release: IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

Dow Jones
·
May 14

Insight Molecular Diagnostics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
May 12

Insight Molecular Diagnostics schedules Q1 2026 results webcast

Reuters
·
May 07

Insight Molecular refiles bylaws exhibit after clerical error in 10-K attachment

Reuters
·
May 01

Broadwood Partners buys 570,184 Insight Molecular Diagnostics shares for $2.04 million

Reuters
·
Apr 28

Broadwood Partners buys $633,117 Insight Molecular Diagnostics shares

Reuters
·
Apr 21

Insight Molecular Diagnostics highlights new real-world GraftAssure data at EFI2026

Reuters
·
Apr 14

Analysts Are Bullish on Top Healthcare Stocks: Insight Molecular Diagnostics (IMDX), Tango Therapeutics (TNGX)

TIPRANKS
·
Mar 27